Get the Stockscreener App
4.08
30.73%
-1.81
After Hours:
4.10
0.02
+0.49%
Cdt Equity Inc stock is traded at $4.08, with a volume of 142.29K.
It is down -30.73% in the last 24 hours and down -73.91% over the past month.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
See More
Previous Close:
$5.89
Open:
$5.94
24h Volume:
142.29K
Relative Volume:
2.23
Market Cap:
$19.27M
Revenue:
-
Net Income/Loss:
$-20.70M
P/E Ratio:
-0.000615
EPS:
-6633.8863
Net Cash Flow:
$-15.13M
1W Performance:
+3.29%
1M Performance:
-73.91%
6M Performance:
-95.84%
1Y Performance:
-99.87%
1-Day Range:
$3.715
$5.94
1-Week Range:
$3.64
$6.22
52-Week Range:
$3.64
$4,200.00
Cdt Equity Inc Stock (CDT) Company Profile
Name
Cdt Equity Inc
Sector
Industry
Phone
(646) 491 9132
Address
4851 TAMIAMI TRAIL NORTH, NAPLES
Compare CDT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDT
Cdt Equity Inc
|
4.08 | 27.82M | 0 | -20.70M | -15.13M | -6,633.89 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 113.64B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 81.18B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.78B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cdt Equity Inc Stock (CDT) Latest News
Which stocks are experiencing notable movement on Friday? - ChartMill
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
CDT Equity Inc. (CDT) stock price, news, quote and history - Yahoo Finance UK
CDT Notes Sarborg Publication of PRISM Framework Expanding AI - The Manila Times
CDT Equity Inc. (CDTTW) Fundamental Analysis - Meyka
CDT PE Ratio & Valuation, Is CDT Overvalued - Intellectia AI
CDT Equity Delays Annual Report Filing - The Globe and Mail
12 Health Care Stocks Moving In Thursday's After-Market SessionBullfrog AI Hldgs (NASDAQ:BFRG), CDT Eq - Benzinga
CDT (NASDAQ: CDT) expands at‑the‑market capacity to $76.1M under AGP pact - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Morning Market Movers: ELAB, BATL, CSHR, CDT See Big Swings - RTTNews
CDT Equity files for non-timely 10-K with US SEC - marketscreener.com
CDT Equity Files For Non-Timely 10-K With US SEC - TradingView
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
CDT Surges 32% on New Patents, But Will It Hold Above $6? - Bitget
CDT Equity (CDT) notifies late 10-K; expects filing within 15 days - Stock Titan
Which stocks are experiencing notable movement on Tuesday? - ChartMill
Morning Market Movers: APLS, PEPG, CDT, PHR See Big Swings - RTTNews
Discover the top movers in Tuesday's pre-market session. - ChartMill
Why Virgin Galactic Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Benzinga
CDT Equity (CDT) entities cashlessly exercise all pre-funded warrants - Stock Titan
CDT Equity (CDT) discloses pre-funded warrants from Sarborg deal - Stock Titan
Mark Taylor Discloses Investment in CDT Equity Inc. with 43.79% Stake - TradingView
Sarborg deal leaves CDT Equity (CDT) with investor group owning 43.79% of shares - Stock Titan
CDT Crashes 24% in Intraday Trading Amid Patent Filing and Market Doldrums — What’s Next? - Bitget
CDT Equity files patents for tapinarof combination therapy By Investing.com - Investing.com South Africa
CDT Equity announces reverse stock split - MSN
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings - Bitget
CDT Equity files patents for tapinarof combination therapy - Investing.com
CDT Equity Announces 1-for-25 Reverse Stock Split - The Globe and Mail
CDT Equity approves 1-for-25 reverse stock split effective Thursday - Investing.com Australia
Conduit to change name to CDT Equity - MSN
Cdt Equity Inc. announces reverse stock split - MarketScreener
Cdt Equity Inc. Announces Reverse Stock Split - TradingView
Reverse split shrinks CDT Equity (NASDAQ: CDT) share count 25-to-1 - Stock Titan
CDT Equity Inc. Announces Reverse Stock Split - bitget.com
Cdt identifies rare disease opportunities through Sarborg Signature Analysis, advancing out-licensing strategy - MarketScreener
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy - The Manila Times
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
If You Invested $1,000 in CDT Equity (CDT) - Stock Titan
CDT Equity Inc. 8-K Filing March 17, 2026: Company Details, Address, Trading Symbol, and Emerging Growth Status - Minichart
CDT Equity Shareholders Approve Major Capital Restructuring Measures - TipRanks
CDT Equity (NASDAQ: CDT) wins backing for large share issues and Cayman move - Stock Titan
Latest CDT NewsConduit Pharmaceuticals to Present at the Op... - Stock Titan
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth - Bitget
Cdt Equity stockholders approve all proposals at special meeting, positioning the company for next phase of growth - marketscreener.com
Cdt Equity Stockholders Approve All Proposals At Special Meeting, Positioning The Company For Next Phase Of Growth - TradingView
CDT Equity to map asset portfolio against rare disease database By Investing.com - Investing.com India
Cdt Equity Inc Stock (CDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
3.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):